Table 2. The relevant studies and possible therapeutic targets of CAR-T cell therapy for colorectal cancer.
| Target | NCT number | Disease type | N | Phase | Status | First posted | Last update posted | Ref. |
|---|---|---|---|---|---|---|---|---|
| CEA | NCT02349724 | Colorectal cancer | 75 | I | Unknown status | 2015-01-29 | 2017-04-25 | (47) |
| NCT02416466 | Liver metastases | 8 | I | Completed | 2015-04-15 | 2019-03-26 | NA | |
| NCT02850536 | Liver metastases | 5 | I | Completed | 2016-08-01 | 2021-10-21 | (48) | |
| NCT02959151 | Colorectal cancer metastatic | 20 | I/II | Unknown status | 2016-11-08 | 2016-11-08 | NA | |
| NCT04348643 | Colorectal cancer | 40 | I/II | Recruiting | 2020-04-16 | 2020-09-01 | NA | |
| NCT04513431 | Stage III colorectal cancer/colorectal cancer liver metastasis | 18 | eI | Not yet recruiting | 2020-08-14 | 2020-08-14 | NA | |
| NCT05240950 | Colorectal cancer liver metastasis | 18 | I | Recruiting | 2022-02-15 | 2022-03-11 | NA | |
| NCT05396300 | Colorectal cancer | 60 | I | Recruiting | 2022-05-31 | 2022-06-02 | NA | |
| NCT05415475 | Colorectal cancer | 36 | I | Recruiting | 2022-06-13 | 2022-07-22 | NA | |
| NKG2D | NCT03018405 | Colorectal cancer | 146 | I/II | Unknown status | 2017-01-12 | 2019-09-19 | (49) |
| NCT03310008 | Colon cancer liver metastasis | 36 | I | Active, not recruiting | 2017-10-16 | 2020-06-16 | NA | |
| NCT03370198 | Colon cancer liver metastasis | 1 | I | Active, not recruiting | 2017-12-12 | 2020-06-18 | NA | |
| NCT03692429 | Unresectable metastatic colorectal cancer | 49 | I | Recruiting | 2018-10-02 | 2020-11-20 | (50) | |
| NCT04107142 | Colorectal cancer | 10 | I | Unknown status | 2019-09-27 | 2019-09-27 | NA | |
| NCT04550663 | Colorectal cancer | 10 | I | Not yet recruiting | 2020-09-16 | 2020-09-23 | NA | |
| NCT05248048 | Refractory metastatic colorectal cancer | 9 | eI | Recruiting | 2022-02-21 | 2022-02-21 | NA | |
| EGFR | NCT03152435 | EGFR-positive colorectal cancer | 20 | I/II | Unknown status | 2017-05-15 | 2017-08-16 | NA |
| NCT03542799 | Metastatic colorectal cancer | 20 | I | Unknown status | 2018-05-31 | 2018-05-31 | NA | |
| GUCY2C | NCT05287165 | Colorectal cancer | 19 | eI | Recruiting | 2022-03-18 | 2022-03-18 | NA |
| NCT05319314 | Colorectal cancer | 30 | I | Recruiting | 2022-04-08 | 2022-08-05 | NA | |
| HER2 | NCT03740256 | Colorectal cancer | 45 | I | Recruiting | 2018-11-14 | 2022-08-29 | (51) |
| CD133 | NCT02541370 | Colorectal cancer | 20 | I/II | Completed | 2015-09-04 | 2019-12-17 | (52) |
| MUC1 | NCT02617134 | Colorectal carcinoma | 20 | I/II | Unknown status | 2015-11-30 | 2016-12-06 | NA |
| NCT05239143 | Colorectal cancer | 100 | I | Recruiting | 2022-02-14 | 2022-07-25 | NA | |
| EpCAM | NCT03013712 | Colon cancer | 60 | I/II | Unknown status | 2017-01-06 | 2017-01-06 | NA |
| NCT05028933 | Colorectal cancer | 48 | I | Recruiting | 2021-08-31 | 2022-01-13 | NA | |
| C-Met | NCT03638206 | Colorectal cancer | 73 | I/II | Recruiting | 2018-08-20 | 2019-12-11 | NA |
| MSLN | NCT04503980 | Colorectal cancer | 10 | eI | Recruiting | 2020-08-07 | 2020-08-07 | NA |
| NCT05089266 | Colorectal cancer | 30 | I | Not yet recruiting | 2021-10-22 | 2021-10-22 | NA | |
| B7-H3 | NCT05190185 | Colorectal cancer | 18 | I | Recruiting | 2022-01-13 | 2022-01-13 | NA |
CEA, carcinoembryonic antigen; eI, early phase 1; NKG2D, natural killer group 2D; EGFR, epidermal growth factor receptor; GUCY2C, guanylyl cyclase C; HER2, human epidermal growth factor receptor 2; CD133, prominin-1; MUC1, mucin 1; EpCAM, epithelial cell adhesion molecule; c-Met, cellular mesenchymal-epithelial transition factor; MSLN, mesothelin; B7-H3, B7 homolog 3; NA, not applicable. CAR, chimeric antigen receptor.